Pat T. Foley

Level 1, 80 Drummond Street
Carlton, VIC 3053, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Author Correction: Governance and resilience as entry points for transforming food systems in the countdown to 2030.

Author Correction: Governance and resilience as entry points for transforming food systems in the countdown to 2030.

Journal: Nature food

Published: February 26, 2026

Real-World Efficacy and Drug Survival of Adalimumab in Australian Patients With Psoriasis.

Real-World Efficacy and Drug Survival of Adalimumab in Australian Patients With Psoriasis.

Journal: The Australasian journal of dermatology

Published: August 14, 2025

Food systems performance evaluated against targets and benchmarks reveals urgent gaps and a path to 2050.

Food systems performance evaluated against targets and benchmarks reveals urgent gaps and a path to 2050.

Journal: Nature food

Published: July 28, 2025

Author Correction: Governance and resilience as entry points for transforming food systems in the countdown to 2030.

Author Correction: Governance and resilience as entry points for transforming food systems in the countdown to 2030.

Journal: Nature food

Published: February 19, 2025

Development of an Australasian Dermatology Registry.

Development of an Australasian Dermatology Registry.

Journal: The Australasian journal of dermatology

Published: February 10, 2025

Governance and resilience as entry points for transforming food systems in the countdown to 2030.

Governance and resilience as entry points for transforming food systems in the countdown to 2030.

Journal: Nature food

Published: June 05, 2024

The state of food systems worldwide in the countdown to 2030.

The state of food systems worldwide in the countdown to 2030.

Journal: Nature food

Published: July 19, 2023

Immunogenicity and pharmacokinetics of guselkumab among patients with moderate-to-severe psoriasis in VOYAGE-1 and VOYAGE-2.

Immunogenicity and pharmacokinetics of guselkumab among patients with moderate-to-severe psoriasis in VOYAGE-1 and VOYAGE-2.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: March 23, 2023

Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance.

Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: March 11, 2022

Ixekizumab provides persistent improvements in health-related quality of life and the sexual impact associated with moderate-to-severe genital psoriasis in adult patients during a 52-week, randomised, placebo-controlled, phase 3 clinical trial.

Ixekizumab provides persistent improvements in health-related quality of life and the sexual impact associated with moderate-to-severe genital psoriasis in adult patients during a 52-week, randomised, placebo-controlled, phase 3 clinical trial.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: June 09, 2021

Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2.

Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2.

Journal: The British journal of dermatology

Published: June 07, 2021

Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2).

Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2).

Journal: The British journal of dermatology

Published: February 04, 2021

Showing 1-12 of 28

Last Updated: 09/26/2026